Darryle Schoepp

Dr. Schoepp has over thirty years of experience in the discovery and development of innovative Neuroscience therapeutics in the pharmaceutical industry. This includes 20 years at Eli Lilly as a scientist and leader of the Neuroscience research department, and 12 years at Merck as the Neuroscience research therapeutic area leader. At. Merck his team built a pipeline of innovative first-class agents for Alzheimer’s disease, Parkinson’s disease, pain/migraine, and schizophrenia. His group made important contributions to the pioneering trials of the BACE inhibitor verubecestat in prevention trials for Alzheimer’s disease and developed the tau PET imaging agent MK-6420.

Dr. Schoepp has over 200 publications and is an inventor of 15 US patents. He is recognized for having made major contributions in the investigation of glutamate receptor pharmacology and therapeutics with the discovery of novel first-in-class agents for psychiatric and neurological diseases. Schoepp’s honors include the 2002 Pharmacia / ASPET Award for Experimental Therapeutics for his research on the experimental therapeutics of metabotropic glutamate receptors in psychiatry and the 2007 Ray Fuller / ASPET Lecturer in Neurosciences in recognition of translational pharmacology work in the glutamate field.

Dr. Schoepp received his bachelor’s degree in Pharmacy from North Dakota State University and his doctoral degree in Pharmacology and Toxicology from West Virginia University.